Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507532 | 0.86 | SCN9A (0.52) | SCN9AITKSCN10A | |
| SCHEMBL6507806 | 0.85 | SCN9A (0.57) | SCN9AITKSCN10A | |
| SCHEMBL6502841 | 0.85 | SCN9A (0.53) | SCN9AITKSCN10A | |
| SCHEMBL6504813 | 0.82 | PTGER1 (0.44) | PTGER1PPIAITK | |
| SCHEMBL6502010 | 0.81 | SCN9A (0.51) | SCN9AGRM5ITKSCN10A | |
| SCHEMBL6470433 | 0.80 | SCN9A (0.48) | SCN9AITKSCN10A | |
| SCHEMBL6468124 | 0.80 | ITK (0.44) | SCN9AITKCYP11B2 | |
| SCHEMBL6506576 | 0.80 | LMNA (0.46) | SCN9AITK | |
| SCHEMBL6499446 | 0.79 | SCN9A (0.47) | SCN9AITKSCN10A | |
| SCHEMBL6467585 | 0.79 | SCN9A (0.44) | SCN9AITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | SCN9A 4159/4885PTGER1 749/4885PTGER4 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.